finance.yahoo.com
Positivefinance.yahoo.com ·
Anaptysbio Anab One Best Performing
Private Sector DevelopmentBusiness ClimateInspections Licensing And Per…Business Environment
Topic context
This topic has been covered 275727 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedAnaptysBio (ANAB) is a biotech royalty management company. The price target cut and spinoff are company-specific events with no broad sector impact. No direct commercial mechanism affecting product prices, supply chains, or margins is identified.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Piper Sandler reduced AnaptysBio price target from $95 to $93 on May 4, 2026.
- AnaptysBio spun off First Tracks Biotherapeutics (TRAX) in April 2026.
- AnaptysBio now operates as a royalty management company.
- Delaware Chancery Court dismissed Tesaro's breach of contract claim against AnaptysBio on April 24, 2026.
Related stories
finance.yahoo.com
Ncmi Q1 2026 Earnings Transcript
finance.yahoo.com
Transcript Valneva Q1 2026 Earnings
finance.yahoo.com
Aytu Aytu Q3 2026 Earnings
fool.com
Keysight Keys Q2 2026 Earnings Transcript
livemint.com